Developer · United Kingdom
Beckley Psytech Limited
Clinical-stage biopharmaceutical company developing rapid-acting, short-duration psychedelic medicines for neuropsychiatric disorders, led by intranasal 5-MeO-DMT benzoate (BPL-003) and IV psilocin benzoate (ELE-101). Founded in 2019 and headquartered in Oxford, UK; acquired by atai Life Sciences in November 2025 to form AtaiBeckley.
Pipeline (2)
- BPL-003 (intranasal 5-MeO-DMT benzoate)Psychedelic5-HT1A AgonistLed by Atai Beckley N.V. (AtaiBeckley)
- Treatment-resistant depressionPhase 2Active
- Alcohol use disorderPhase 2Completed
- ELE-101 (intravenous psilocin benzoate)Psychedelic5-HT2A AgonistLed by Atai Beckley N.V. (AtaiBeckley)
- Major depressive disorderPhase 1/2Active
Deals & partnerships
- BPL-003 (intranasal 5-MeO-DMT benzoate)Led by Atai Beckley N.V. (AtaiBeckley)
- ELE-101 (intravenous psilocin benzoate)Led by Atai Beckley N.V. (AtaiBeckley)Licensor Eleusis Therapeutics Limited
- Nov 5, 2025Acquisitionatai Life Sciences completes acquisition of Beckley Psytech to form AtaiBeckleyAll-share strategic combination (announced June 2, 2025; Beckley valued at ~$390M) in which atai Life Sciences (renamed Atai Beckley N.V., Nasdaq: ATAI) acquired Beckley Psytech Limited. The deal was conditioned on positive BPL-003 Phase 2b topline data and closed November 5, 2025 after ~98% shareholder approval on November 4, 2025; Beckley shareholders received ~105 million new atai shares. BPL-003 and ELE-101 carried into the combined company.
- Oct 21, 2022AcquisitionBeckley Psytech acquires Eleusis Therapeutics, adding ELE-101 to its pipelineAll-equity acquisition in which Beckley Psytech acquired 100% of Eleusis Therapeutics Limited, gaining full development and commercial rights to ELE-101, an intravenous formulation of psilocin (the active metabolite of psilocybin). Eleusis CEO Shlomi Raz joined as Beckley's Chief Business Officer. Announced October 23, 2022; consideration undisclosed.
Catalysts · 0 upcoming · 2 reported
Recently reported
- 2025-01-28met
BPL-003 (intranasal 5-MeO-DMT benzoate)forAlcohol use disorderTopline data
BPL-003 Phase 2a open-label AUD study positive topline: single 10 mg dose + psychological support cut heavy drinking days (56%->13%) and raised abstinent days (33%->81%) at Week 12, with 50% maintaining complete abstinence over 3 months; well tolerated, no serious/severe AEs.
- 2024-12-16met
ELE-101 (intravenous psilocin benzoate)forMajor depressive disorderTopline data
Positive Phase 2a topline: single IV dose of ELE-101 produced mean >20-point MADRS reduction sustained to 3 months in MDD (n=6); 4/4 evaluable subjects in remission at Day 90
Recent activity
- Oct 16, 2025Phase changeBPL-003 (intranasal 5-MeO-DMT benzoate)·Treatment-resistant depressionPhase 2FDA granted Breakthrough Therapy Designation for BPL-003 in TRD; Phase 3 planned ~Q2 2026.source ↗
- Jul 1, 2025Phase changeBPL-003 (intranasal 5-MeO-DMT benzoate)·Treatment-resistant depressionPhase 2Positive Phase 2b topline: single 8 mg / 12 mg dose produced rapid significant MADRS reductions vs 0.3 mg comparator at Day 29, largely maintained to Day 57.source ↗
- Jan 28, 2025ReadoutBPL-003 (intranasal 5-MeO-DMT benzoate)·Alcohol use disordermetBPL-003 Phase 2a open-label AUD study positive topline: single 10 mg dose + psychological support cut heavy drinking days (56%->13%) and raised abstinent days (33%->81%) at Week 12, with 50% maintaining complete abstinence over 3 months; well tolerated, no serious/severe AEs.source ↗
- Dec 16, 2024ReadoutELE-101 (intravenous psilocin benzoate)·Major depressive disordermetPositive Phase 2a topline: single IV dose of ELE-101 produced mean >20-point MADRS reduction sustained to 3 months in MDD (n=6); 4/4 evaluable subjects in remission at Day 90source ↗
- Jun 20, 2024Phase changeELE-101 (intravenous psilocin benzoate)·Major depressive disorderPhase 1/2Initial Phase 1 results reported (well tolerated, dose-proportional PK, high-intensity short-duration psychedelic experiences) and first patients dosed in the open-label Phase 2a (MDD) portion.source ↗
- Oct 27, 2022Phase changeELE-101 (intravenous psilocin benzoate)·Major depressive disorderPhase 1Phase 1/2a trial NCT05434156 initiated (study start date); Part 1 single-ascending-dose study in healthy adults.source ↗
Trials recruiting · 1 recruiting of 4 sponsored
Open-Label Phase 2a Study of BPL-003 in Treatment Resistant Depression
Competitive landscape
Other companies developing against Beckley Psytech Limited's targets or indications.
- COMPASS Pathways plc1 compound5-HT2ATreatment-resistant depressionMajor depressive disorder
- Alto Neuroscience, Inc.3 compoundsTreatment-resistant depressionMajor depressive disorder
- Atai Beckley N.V. (AtaiBeckley)1 compound5-HT2ATreatment-resistant depression
- Definium Therapeutics, Inc.1 compound5-HT2AMajor depressive disorder
- Delix Therapeutics, Inc.1 compound5-HT2AMajor depressive disorder
- GH Research PLC1 compound5-HT2ATreatment-resistant depression
- Gilgamesh Pharmaceuticals, Inc.2 compounds5-HT2AMajor depressive disorder
- Helus Pharma2 compounds5-HT2AMajor depressive disorder
- Intra-Cellular Therapies, Inc.2 compounds5-HT2AMajor depressive disorder
- Mindset Pharma Inc.1 compound5-HT2AMajor depressive disorder
- Taisho Pharmaceutical Co., Ltd.2 compoundsTreatment-resistant depressionMajor depressive disorder
- Vanda Pharmaceuticals Inc.2 compounds5-HT2AMajor depressive disorder
